RecruitingPhase 2interventionalRules rewrite

Phase 2: testing Ticagrelor: an oral, direct-acting, reversibly binding P2Y12 receptor antagonist for Chronic Kidney Disease (CKD)

Q: Is NCT07911124 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

Q: What phase is NCT07911124?

Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Q: Can PlainTrials tell me if I qualify for NCT07911124?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

The goal of this clinical trial is to learn if treatment with ticagrelor tablets can decrease inflammation in patients with Chronic Kidney Disease (CKD). Inflammation is thought to contribute to the risk of heart disease which is the leading cause of death in patients with CKD.

Official registry: https://clinicaltrials.gov/study/NCT07911124 · University of Arkansas · enrollment listed as 230

What this phase means

Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Ticagrelor: an oral, direct-acting, reversibly binding P2Y12 receptor antagonist, or Placebo. The registry lists allocation as randomized. The goal of this clinical trial is to learn if treatment with ticagrelor tablets can decrease inflammation in patients with Chronic Kidney Disease (CKD).

They plan to enroll about 230 people at Little Rock. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

A Randomized Double-Blind Placebo-Controlled Phase II Clinical Trial to Investigate the Effect of Platelet Inhibition With Ticagrelor to Reduce Inflammation and Surrogate Cardiovascular Markers in Chronic Kidney Disease

Interventions: Ticagrelor: an oral, direct-acting, reversibly binding P2Y12 receptor antagonist, Placebo

Primary outcome (registry wording): Aim 1: post-treatment IL-1β value

Who it is for (from inclusion criteria)

Ages 21 Years to 75 Years
Population 1: CKD Participants
Age 21 to 75 years at the time of screening, inclusive
Diagnosis of chronic kidney disease with estimated glomerular filtration rate (eGFR) \<45 ml/min/1.73m² as calculated by the CKD-EPI equation, confirmed from medical records or laboratory results
Currently receiving the maximally tolerated or labeled dose of a renin-angiotensin-aldosterone system inhibitor (RAASi) as guideline-directed medical therapy (GDMT), or documentation of the reason for not receiving RAASi (e.g., intolerance, contraindication)
Population 2: Control Participants
Normal kidney function, defined as eGFR \>60 ml/min/1.73m² (CKD-EPI equation) and urinary albumin-to-creatinine ratio (UACR) \<30 mg/g, confirmed from medical records or laboratory results

Who the registry excludes

Population 1: CKD Participants
Unwilling or unable to participate in the protocol or comply with its components
End-stage renal disease (defined as receiving peritoneal dialysis or hemodialysis) or any prior solid organ or bone marrow transplant. Rationale: dialysis directly affects platelet function and would confound the primary endpoint
Acute kidney injury superimposed on CKD at the time of screening
Acute coronary syndrome, acute myocardial infarction, or acute cerebrovascular event within 6 months prior to screening. Rationale: these participants are likely receiving P2Y12 inhibitor therapy, and their enrollment would confound the primary endpoint
Hospitalization, major surgery, or use of systemic antibiotics within 1 month prior to screening. Rationale: these events are potentially associated with acute inflammatory changes that would confound baseline cytokine measurements
Blood dyscrasias, active bleeding of any site, or a known bleeding diathesis

Public study contact (from the registry)

Jonathan Young

501-526-7984

jayoung@uams.edu

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

University of Arkansas for Medical Sciences — Little Rock, Arkansas (recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland

Immune System Related Kidney Disease

Kidney diseases related to the immune system include, nephrotic syndrome, glomerulonephritis, membranous nephropathy, lupus nephritis, and nephritis associated with connective tissue disorders. This study will allow researchers to admit and follow patients suffering from autoimmune diseases of the kidney.

NCT00001979 · Official ClinicalTrials.gov record · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

RecruitingNot a traditional drug phaseAnn Arbor, Michigan

University of Michigan "Nephrology Research BioBank"

The purpose of the study is to create a Nephrology Tissue Biobank enabling the study of kidney disease from the perspectives of epidemiology, genetics and molecular biology.

NCT00381121 · Official ClinicalTrials.gov record · University of Michigan

RecruitingNot a traditional drug phaseBerlin, State of Berlin

Not a traditional drug phase: Sodium propionate for CKD (Chronic Kidney Disease) Stage 5D

Pro-Kids is a multi-center, neither you nor the study doctors know who gets the real treatment, randomly assigned and compared with a dummy treatment intervention study in children with chronic kidney disease. The investigators address the effect of a dietary food supplementation of propionic acid on the immune system and the function of the intestinal barrier in CKD patients treated with hemodialysis.

NCT05858437 · Official ClinicalTrials.gov record · Charite University, Berlin, Germany

FAQ about this NCT record

Is NCT07911124 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07911124?

Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07911124?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary